c-Kit (D816I)

KIT · Variant type: point · HGVS: p.D816I

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Avapritinib	99.7%	0.3%	97.73
2	Pralsetinib	99.2%	0.8%	93.43
3	Ripretinib	98.8%	1.2%	92.95
4	Dasatinib	97.3%	2.7%	87.97
5	Brigatinib	96.7%	3.3%	82.96
6	Nintedanib	96.2%	3.8%	90.23
7	Fostamatinib	95.5%	4.5%	96.74
8	Mitapivat	95.4%	4.6%	100.00
9	Selpercatinib	94.8%	5.2%	96.72
10	Pacritinib	94.7%	5.3%	88.64
11	Gilteritinib	93.6%	6.4%	88.97
12	Bosutinib	90.2%	9.8%	87.22
13	Sunitinib	87.1%	12.9%	91.73
14	Apatinib	86.8%	13.3%	97.73
15	Alectinib	83.0%	17.0%	95.49
16	Umbralisib	82.9%	17.1%	98.74
17	Erdafitinib	82.7%	17.3%	95.71
18	Fedratinib	81.8%	18.2%	96.21
19	Vandetanib	78.5%	21.5%	95.74
20	Capivasertib	77.0%	23.0%	96.48
21	Pazopanib	76.0%	24.0%	97.49
22	Ponatinib	73.4%	26.6%	78.23
23	Alpelisib	69.8%	30.2%	97.22
24	Entrectinib	69.6%	30.4%	93.69
25	Upadacitinib	69.0%	31.0%	97.98

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Avapritinib	99.7%	—	—
Pralsetinib	99.2%	—	—
Ripretinib	98.8%	—	—
Dasatinib	97.3%	—	—
Brigatinib	96.7%	—	—
Nintedanib	96.2%	—	—
Fostamatinib	95.5%	—	—
Mitapivat	95.4%	—	—
Selpercatinib	94.8%	—	—
Pacritinib	94.7%	—	—
Gilteritinib	93.6%	—	—
Bosutinib	90.2%	—	—
Sunitinib	87.1%	—	—
Apatinib	86.8%	—	—
Alectinib	83.0%	—	—
Umbralisib	82.9%	—	—
Erdafitinib	82.7%	—	—
Fedratinib	81.8%	—	—
Vandetanib	78.5%	—	—
Capivasertib	77.0%	—	—
Pazopanib	76.0%	—	—
Ponatinib	73.4%	—	—
Alpelisib	69.8%	—	—
Entrectinib	69.6%	—	—
Upadacitinib	69.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.9ms